Edition:
India

Lupin Ltd (LUPN.NS)

LUPN.NS on National Stock Exchange of India

864.25INR
3:55pm IST
Change (% chg)

Rs-3.35 (-0.39%)
Prev Close
Rs867.60
Open
Rs838.50
Day's High
Rs867.60
Day's Low
Rs835.00
Volume
2,961,143
Avg. Vol
1,904,695
52-wk High
Rs986.10
52-wk Low
Rs719.80

Latest Key Developments (Source: Significant Developments)

Lupin Ltd Says U.S. FDA Classifies Inspection Of Pithampur Unit-2 As OAI
Tuesday, 23 Apr 2019 

April 23 (Reuters) - Lupin Ltd ::U.S. FDA CLASSIFIES INSPECTION OF LUPIN''S PITHAMPUR (INDORE) UNIT-2 FACILITY AS OAI.U.S. FDA STATES THAT FACILITY MAY BE SUBJECT TO REGULATORY OR ADMINISTRATIVE ACTION.U.S. FDA SAYS THAT IT MAY WITHHOLD APPROVAL OF ANY PENDING APPLICATIONS OR SUPPLEMENTS IN WHICH THIS FACILITY IS LISTED.DOES NOT BELIEVE THAT THIS CLASSIFICATION WILL IMPACT EXISTING REVENUES FROM OPERATIONS OF THIS FACILITY.CO IS IN PROCESS OF SENDING FURTHER UPDATES OF ITS CORRECTIVE ACTIONS TO THE U.S. FDA.  Full Article

Lupin Gets FDA Approval For Fluoxetine Tablets USP
Tuesday, 16 Apr 2019 

April 16 (Reuters) - Lupin Ltd ::RECEIVES FDA APPROVAL FOR FLUOXETINE TABLETS USP.  Full Article

Lupin Ltd Says Lupin Bioresearch Centre Completes Fifth Successful U.S. FDA Inspection
Wednesday, 3 Apr 2019 

April 3 (Reuters) - Lupin Ltd ::LUPIN BIORESEARCH CENTRE COMPLETES FIFTH SUCCESSFUL U.S. FDA INSPECTION.SUCCESSFUL COMPLETION OF U.S FDA INSPECTION AT ITS LUPIN BIORESEARCH CENTRE (LBC) WITHOUT ANY OBSERVATIONS.  Full Article

Lupin Says Pithampur Unit-3 Gets EIR From U.S. FDA
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Lupin Ltd ::PITHAMPUR UNIT-3 GETS EIR FROM U.S. FDA.SAYS INSPECTION WAS CONDUCTED BETWEEN OCTOBER 8, 2018 TO OCTOBER 18, 2018.LUPIN - PITHAMPUR UNIT-3 IS INVOLVED IN MANUFACTURE OF METERED DOSE INHALERS, DRY POWDER INHALERS AND TOPICAL FORMULATIONS FOR REGULATED MARKETS.  Full Article

Lupin Says Recall Of Testosterone Topical Solution Was Classified As Class III Recall By USFDA
Tuesday, 2 Apr 2019 

April 2 (Reuters) - Lupin Ltd ::RECALL OF 3,200 BOTTLES OF TESTOSTERONE TOPICAL SOLUTION WAS CLASSIFIED AS CLASS III RECALL BY USFDA.  Full Article

Lupin Gets US FDA Approval For Sildenafil Tablets
Monday, 25 Mar 2019 

March 25 (Reuters) - Lupin Ltd ::GETS US FDA APPROVAL FOR SILDENAFIL TABLETS USP.  Full Article

Lupin Gets USFDA Approval For Atorvastatin Calcium Tablets Usp
Thursday, 7 Mar 2019 

March 7 (Reuters) - Lupin Ltd ::SAYS LUPIN RECEIVES FDA APPROVAL FOR ATORVASTATIN CALCIUM TABLETS USP.SAYS DRUG INDICATED TO LOWER CHOLESTEROL IN BLOOD FOR ADULTS AND CHILDREN OVER 10 YEARS OF AGE.  Full Article

Lupin Says In Alliance With Natco Gets FDA Approval For Imatinib Mesylate Tablets
Tuesday, 5 Mar 2019 

March 5 (Reuters) - Lupin Ltd ::LUPIN - IN ALLIANCE WITH NATCO RECEIVES FDA APPROVAL FOR IMATINIB MESYLATE TABLETS.  Full Article

India's Lupin Launches Ranolazine Er Tablets In U.S
Thursday, 28 Feb 2019 

Feb 28 (Reuters) - Lupin Ltd ::SAYS LAUNCHES GENERIC RANOLAZINE ER TABLETS IN U.S..SAYS RANOLAZINE IS INDICATED FOR THE TREATMENT OF CHRONIC ANGINA.  Full Article

Lupin Launches Generic Minocycline Hydrochloride ER Tablets USP
Tuesday, 26 Feb 2019 

Feb 26 (Reuters) - Lupin Ltd ::SAYS CO LAUNCHES GENERIC MINOCYCLINE HYDROCHLORIDE ER TABLETS USP.  Full Article

BUZZ-India's Lupin shares fall on potential U.S. FDA admin action on plant

** Drugmaker Lupin Ltd' shares fall as much as 3.8 pct to 835 rupees, their biggest daily pct drop since March 18